Literature DB >> 9516866

Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group.

D Strother1, J van Hoff, P V Rao, E I Smith, R C Shamberger, E C Halperin, K J Murray, R P Castleberry.   

Abstract

We analysed the 2-year event-free survival (EFS) of 49 patients 1 year of age and older, with stage 2B or 3 neuroblastoma, treated on Pediatric Oncology Group protocols 8742 and 9244, with respect to the degree of tumour resection at diagnosis. The 2-year EFS rate for 21 children whose tumours were completely resected at diagnosis was 85% (SE = 10%) compared with an EFS rate of 70% (SE = 9%) for the 28 children whose tumours were incompletely resected at diagnosis. Despite the observed trend in favour of complete resection, these EFS curves were not statistically significantly different (P = 0.259). Patients with favourable Shimada histology tumours had an EFS rate of 92% (SE = 7%) compared with a rate of 58% (SE = 15%) for patients with unfavourable histology tumours. EFS curves for the two histologic groups were significantly different (P = 0.009). The impact of aggressive surgery and adjuvant chemotherapy on the outcome of patients with biologically favourable regional neuroblastoma is still unclear.

Entities:  

Mesh:

Year:  1997        PMID: 9516866     DOI: 10.1016/s0959-8049(97)00293-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Neuroblastoma with primary pleural involvement: an unusual presentation.

Authors:  Matthew Tay; Jeevesh Kapur
Journal:  Pediatr Radiol       Date:  2010-11-16

2.  Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

Authors:  David L Baker; Mary L Schmidt; Susan L Cohn; John M Maris; Wendy B London; Allen Buxton; Daniel Stram; Robert P Castleberry; Hiroyuki Shimada; Anthony Sandler; Robert C Shamberger; A Thomas Look; C Patrick Reynolds; Robert C Seeger; Katherine K Matthay
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Management and outcome of stage 3 neuroblastoma.

Authors:  Shakeel Modak; Brian H Kushner; Michael P LaQuaglia; Kim Kramer; Nai-Kong V Cheung
Journal:  Eur J Cancer       Date:  2008-11-06       Impact factor: 9.162

4.  Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.

Authors:  Peter E Zage; Morris Kletzel; Kevin Murray; Robert Marcus; Robert Castleberry; Yang Zhang; Wendy B London; Cynthia Kretschmar
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

Review 5.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

6.  Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?

Authors:  John T Lucas; M Beth McCarville; David A Cooper; Mikhail Doubrovin; Daniel Wakefield; Teresa Santiago; Yimei Li; Xingyu Li; Matthew Krasin; Victor Santana; Wayne Furman; Andrew M Davidoff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-26       Impact factor: 7.038

7.  The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.

Authors:  Tyler Maser; Joseph Zagorski; Shannon Kelly; Anna Ostrander; Austin Goodyke; Abhinav Nagulapally; Jeffrey Bond; Yeonhee Park; Giselle Saulnier Sholler
Journal:  Cancer Med       Date:  2020-10-09       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.